Dan Goldstaub

Dan Goldstaub has a diverse work experience in various roles and companies. Dan currently serves as the Co-Founder of PhaseV since January 2023. Prior to this, they held the position of Member at 8400 The Health Network starting in 2018. In 2022, they worked as an Entrepreneur at Arkin Holdings, a Board Member at Cytora Stem, and a Board Member at QRGenetics. In 2021, they were a Speaker at the Israeli Society for HealthTech and held the role of Senior Vice President Development at 1E Therapeutics from May to November. Before that, they had a long tenure at MSD, where they held several positions including Executive Director, Clinical Research, and Director Clinical Research. Dan started their career as the Chief Operating Officer at Tiltan Pharma Ltd in 2008 and co-founded Remunix in 2009.

Dan Goldstaub obtained their Bachelor of Applied Science in Biology/Biological Sciences from Tel Aviv University. Dan then pursued a Master of Science in Biochemistry at Technion - Israel Institute of Technology. Finally, they completed a PhD in the Department of Molecular Genetics at the Weizmann Institute of Science.